Skip to main content
Erschienen in: Pituitary 4/2019

20.06.2019 | Neurosurgery

Role of gamma knife radiosurgery in the treatment of prolactinomas

verfasst von: Jana Ježková, Václav Hána, Mikuláš Kosák, Michal Kršek, Roman Liščák, Josef Vymazal, Ladislav Pecen, Josef Marek

Erschienen in: Pituitary | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Stereotactic radiosurgery is one of the treatment options for prolactinomas, the most commonly used being Gamma Knife Radiosurgery (GKRS). GKRS is indicated mainly in the treatment of dopamine agonist (DA)-resistant prolactinomas. In our study, we report on our experience in treating prolactinoma patients by GKRS.

Methods

Twenty-eight patients were followed-up after GKRS for 26–195 months (median 140 months). Prior to GKRS, patients were treated with DAs and 9 of them (32.1%) underwent previous neurosurgery. Cavernous sinus invasion was present in 16 (57.1%) patients. Indications for GKRS were (i) resistance to DA treatment (17 patients), (ii) drug intolerance (5 patients), or (iii) attempts to reduce the dosage and/or shorten the length of DA treatment (6 patients).

Results

After GKRS, normoprolactinaemia was achieved in 82.1% of patients, out of which hormonal remission (normoprolactinaemia after discontinuation of DAs) was achieved in 13 (46.4%), and hormonal control (normoprolactinaemia while taking DAs) in 10 (35.7%) patients. GKRS arrested adenoma growth or decreased adenoma size in all cases. Two patients (8.3%) developed hypopituitarism after GKRS. Prolactinoma cystic transformation with expansive behaviour, manifested by bilateral hemianopsia, was observed in one patient.

Conclusions

GKRS represents an effective treatment option, particularly for DA-resistant prolactinomas. Normoprolactinaemia was achieved in the majority of patients, either after discontinuation of, or while continuing to take, DAs. Tumour growth was arrested in all cases. The risk of the development of hypopituitarism can be limited if the safe dose to the pituitary and infundibulum is maintained.
Literatur
1.
Zurück zum Zitat Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. N Engl J Med 331(14):904–909CrossRefPubMed Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994) A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline comparative study group. N Engl J Med 331(14):904–909CrossRefPubMed
2.
Zurück zum Zitat Colao A, Di Sarno A, Sarnacchiaro F, Ferona D, Di Renzo G, Merola B, Annunziato L, Lobardi G (1997) Prolactinoma resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 82(3):876–883CrossRefPubMed Colao A, Di Sarno A, Sarnacchiaro F, Ferona D, Di Renzo G, Merola B, Annunziato L, Lobardi G (1997) Prolactinoma resistant to standard dopamine agonists respond to chronic cabergoline treatment. J Clin Endocrinol Metab 82(3):876–883CrossRefPubMed
3.
Zurück zum Zitat Berinder K, Stackenas I, Akre O, Hirschberg AL, Hulting AL (2005) Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up. Clin Endocrinol 63:450–455CrossRef Berinder K, Stackenas I, Akre O, Hirschberg AL, Hulting AL (2005) Hyperprolactinaemia in 271 women: up to three decades of clinical follow-up. Clin Endocrinol 63:450–455CrossRef
4.
Zurück zum Zitat Rains CP, Bryson HM, Cabergoline Fitton A (1995) A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinemia and inhibition lactation. Drug 49:255–279CrossRef Rains CP, Bryson HM, Cabergoline Fitton A (1995) A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinemia and inhibition lactation. Drug 49:255–279CrossRef
5.
Zurück zum Zitat Webster J (1996) A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinemia and inhibition lactation. Drug Saf 14(4):28–238CrossRef Webster J (1996) A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinemia and inhibition lactation. Drug Saf 14(4):28–238CrossRef
6.
Zurück zum Zitat Vilar L, Burke CW (1994) Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine. Clin Endocrinol 41(6):821–826CrossRef Vilar L, Burke CW (1994) Quinagolide efficacy and tolerability in hyperprolactinaemic patients who are resistant to or intolerant of bromocriptine. Clin Endocrinol 41(6):821–826CrossRef
7.
Zurück zum Zitat Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86:5256–5261CrossRefPubMed Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86:5256–5261CrossRefPubMed
8.
Zurück zum Zitat Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K (2008) Prospective study of high-dose cabergoline treatment of prolactinoma in 150 patients. J Clin Endocrinol Metab 93:4721–4727CrossRefPubMed Ono M, Miki N, Kawamata T, Makino R, Amano K, Seki T, Kubo O, Hori T, Takano K (2008) Prospective study of high-dose cabergoline treatment of prolactinoma in 150 patients. J Clin Endocrinol Metab 93:4721–4727CrossRefPubMed
9.
Zurück zum Zitat Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Cjanson P, Vilar L, Borson-Chazot F, Naves L, Brue T, Gatta B, Delemer B, Ciccareli E, Beck-Peccoz P, Caron P, Daly A, Beckers A (2012) Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol 167:651–662CrossRefPubMed Vroonen L, Jaffrain-Rea ML, Petrossians P, Tamagno G, Cjanson P, Vilar L, Borson-Chazot F, Naves L, Brue T, Gatta B, Delemer B, Ciccareli E, Beck-Peccoz P, Caron P, Daly A, Beckers A (2012) Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur J Endocrinol 167:651–662CrossRefPubMed
10.
Zurück zum Zitat Delgrange E, Daems T, Verhelst J, Abs R, Maiter D (2009) Characterization of resistence to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 160:747–752CrossRefPubMed Delgrange E, Daems T, Verhelst J, Abs R, Maiter D (2009) Characterization of resistence to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 160:747–752CrossRefPubMed
11.
Zurück zum Zitat Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe P, Montvernay C, Calender A (2002) Pituitary disease in MEN type 1 (MEN1): data from France-Belgium MEN 1 multicenter study. J Clin Endocrinol Metab 87:457–465CrossRefPubMed Verges B, Boureille F, Goudet P, Murat A, Beckers A, Sassolas G, Cougard P, Chambe P, Montvernay C, Calender A (2002) Pituitary disease in MEN type 1 (MEN1): data from France-Belgium MEN 1 multicenter study. J Clin Endocrinol Metab 87:457–465CrossRefPubMed
12.
Zurück zum Zitat Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485–534CrossRefPubMed Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485–534CrossRefPubMed
13.
Zurück zum Zitat Tanaka S, Link MJ, Brown PD, Stafford SL, Young WF Jr, Pollock BE (2010) Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas. World Neurosurg 74(1):147–153CrossRefPubMed Tanaka S, Link MJ, Brown PD, Stafford SL, Young WF Jr, Pollock BE (2010) Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas. World Neurosurg 74(1):147–153CrossRefPubMed
14.
Zurück zum Zitat Sheehan JP, Pouratian N, Steiner L, Laws ED, Vance ML (2011) Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg 114(2):303–309CrossRefPubMed Sheehan JP, Pouratian N, Steiner L, Laws ED, Vance ML (2011) Gamma Knife surgery for pituitary adenomas: factors related to radiological and endocrine outcomes. J Neurosurg 114(2):303–309CrossRefPubMed
15.
Zurück zum Zitat Choi JY, Chang JH, Chang JW et al (2003) Radiological and hormonal responses of functioning pituitary adenomas after gamma knife radiosurgery. Yonsei Med J 44:602–607CrossRefPubMed Choi JY, Chang JH, Chang JW et al (2003) Radiological and hormonal responses of functioning pituitary adenomas after gamma knife radiosurgery. Yonsei Med J 44:602–607CrossRefPubMed
16.
Zurück zum Zitat Pollock BE, Nippoldt TB, Stafford SL et al (2002) Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization. J Neurosurg 97:525–530CrossRefPubMed Pollock BE, Nippoldt TB, Stafford SL et al (2002) Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization. J Neurosurg 97:525–530CrossRefPubMed
17.
Zurück zum Zitat Sheehan JP, Niranjan A, Sheehan JM et al (2005) Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 102(4):678–691CrossRefPubMed Sheehan JP, Niranjan A, Sheehan JM et al (2005) Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 102(4):678–691CrossRefPubMed
18.
Zurück zum Zitat Ježková J, Hána V, Kršek M et al (2009) Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol 70:732–741CrossRef Ježková J, Hána V, Kršek M et al (2009) Use of the Leksell gamma knife in the treatment of prolactinoma patients. Clin Endocrinol 70:732–741CrossRef
19.
Zurück zum Zitat Vladyka V, Liščák R, Novotný J Jr et al (2003) Radiation tolerance of functioning pituitary tissue in gamma knife surgery for pituitary adenomas. Neurosurgery 52:309–317CrossRefPubMed Vladyka V, Liščák R, Novotný J Jr et al (2003) Radiation tolerance of functioning pituitary tissue in gamma knife surgery for pituitary adenomas. Neurosurgery 52:309–317CrossRefPubMed
20.
Zurück zum Zitat Marek J, Ježková J, Hána V et al (2011) Is it possible to avoid hypopituitarism after irradiation of pituitary adenomas by the Leksell gamma knife? Eur J Endocrinol 164:169–178CrossRefPubMed Marek J, Ježková J, Hána V et al (2011) Is it possible to avoid hypopituitarism after irradiation of pituitary adenomas by the Leksell gamma knife? Eur J Endocrinol 164:169–178CrossRefPubMed
21.
Zurück zum Zitat Novotný J Jr, Novotný J, Vymazal J, Liščák R, Vladyka V (1998) Assessment pf the accuracy of stereotactic target localization using magnetic resonance imaging: phantom study. J Neurosurg 1:99–111 Novotný J Jr, Novotný J, Vymazal J, Liščák R, Vladyka V (1998) Assessment pf the accuracy of stereotactic target localization using magnetic resonance imaging: phantom study. J Neurosurg 1:99–111
22.
Zurück zum Zitat Ježková J, Marek J, Liščák R (2013) Pituitary adenomas. In: Liščák R (ed) Gamma knife radiosurgery. Nova Science, New York, pp 169–188 Ježková J, Marek J, Liščák R (2013) Pituitary adenomas. In: Liščák R (ed) Gamma knife radiosurgery. Nova Science, New York, pp 169–188
23.
Zurück zum Zitat Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guidline. J Clin Endocrinol Metab 96(2):273–288CrossRefPubMed Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JAH (2011) Diagnosis and treatment of hyperprolactinemia: an endocrine society clinical practice guidline. J Clin Endocrinol Metab 96(2):273–288CrossRefPubMed
24.
Zurück zum Zitat Lim YL, Leem W, Kim TS et al (1998) Four years-experience in the treatment of pituitary adenomas with gamma knife radiosurgery. Stereotact Funct Neurosurg 70(Suppl. 1):95–109CrossRefPubMed Lim YL, Leem W, Kim TS et al (1998) Four years-experience in the treatment of pituitary adenomas with gamma knife radiosurgery. Stereotact Funct Neurosurg 70(Suppl. 1):95–109CrossRefPubMed
25.
Zurück zum Zitat Hayashi M, Izawa M, Hiyama H et al (1999) Gamma knife radiosurgery for pituitary adenomas. Stereotact Funct Neurosurg 72(Suppl. 1):111–118CrossRefPubMed Hayashi M, Izawa M, Hiyama H et al (1999) Gamma knife radiosurgery for pituitary adenomas. Stereotact Funct Neurosurg 72(Suppl. 1):111–118CrossRefPubMed
26.
Zurück zum Zitat Kim SH, Huh R, Chang JW et al (1999) Gamma knife radiosurgery for functioning pituitary adenomas. Stereotact Funct Neurosurg 72(Suppl. 1):101–110CrossRefPubMed Kim SH, Huh R, Chang JW et al (1999) Gamma knife radiosurgery for functioning pituitary adenomas. Stereotact Funct Neurosurg 72(Suppl. 1):101–110CrossRefPubMed
27.
Zurück zum Zitat Mokry M, Ramschak-Schwarzer S, Simbrunner J et al (1999) A six year experience with the postoperative radiosurgical management of pituitary adenomas. Stereotact Funct Neurosurg 72(Suppl. 1):88–100CrossRefPubMed Mokry M, Ramschak-Schwarzer S, Simbrunner J et al (1999) A six year experience with the postoperative radiosurgical management of pituitary adenomas. Stereotact Funct Neurosurg 72(Suppl. 1):88–100CrossRefPubMed
28.
Zurück zum Zitat Pan L, Zhang N, Wang EM et al (2000) Gamma knife radiosurgery as a primary treatment for prolactinomas. J Neurosurg 93(Suppl. 3):10–13CrossRefPubMed Pan L, Zhang N, Wang EM et al (2000) Gamma knife radiosurgery as a primary treatment for prolactinomas. J Neurosurg 93(Suppl. 3):10–13CrossRefPubMed
29.
Zurück zum Zitat Landolt AM, Lomax N (2000) Gamma knife radiosurgery for prolactinomas. J Neurosurg 93(Suppl. 3):14–18CrossRefPubMed Landolt AM, Lomax N (2000) Gamma knife radiosurgery for prolactinomas. J Neurosurg 93(Suppl. 3):14–18CrossRefPubMed
30.
Zurück zum Zitat Petrovich Z, Yu C, Gianotta SL, Zee CS et al (2003) Gamma knife radiosurgery for pituitary adenoma: early results. Neurosurgery 53:51–59 (discussion, 59-61) CrossRefPubMed Petrovich Z, Yu C, Gianotta SL, Zee CS et al (2003) Gamma knife radiosurgery for pituitary adenoma: early results. Neurosurgery 53:51–59 (discussion, 59-61) CrossRefPubMed
31.
Zurück zum Zitat Kuo JS, Chen JCT, Cheng Y et al (2004) Gamma knife radiosurgery for benign cavernous sinus tumors: quantitative analysis of treatment outcomes. Neurosurgery 54:1385–1392CrossRefPubMed Kuo JS, Chen JCT, Cheng Y et al (2004) Gamma knife radiosurgery for benign cavernous sinus tumors: quantitative analysis of treatment outcomes. Neurosurgery 54:1385–1392CrossRefPubMed
32.
Zurück zum Zitat Pouratian N, Sheehan J, Jagannathan J et al (2006) Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery 59:255–264CrossRefPubMed Pouratian N, Sheehan J, Jagannathan J et al (2006) Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery 59:255–264CrossRefPubMed
33.
Zurück zum Zitat Castinetti F, Nagai M, Morange I, Dufour H, Caron P, Chanson P, Cortet-Rudelli C, Kuhn JM, Conte-Devolx B, Regis J, Brue T (2009) Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab 94:3400–3407CrossRefPubMed Castinetti F, Nagai M, Morange I, Dufour H, Caron P, Chanson P, Cortet-Rudelli C, Kuhn JM, Conte-Devolx B, Regis J, Brue T (2009) Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab 94:3400–3407CrossRefPubMed
34.
Zurück zum Zitat Liu X, Kano H, Kondziolka D, Park KJ, Iyer A, Shin S, Niranjan A, Flickinger JC, Lunsford LD (2013) Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas. Pituitary 16:68–75CrossRefPubMed Liu X, Kano H, Kondziolka D, Park KJ, Iyer A, Shin S, Niranjan A, Flickinger JC, Lunsford LD (2013) Gamma knife stereotactic radiosurgery for drug resistant or intolerant invasive prolactinomas. Pituitary 16:68–75CrossRefPubMed
35.
Zurück zum Zitat Elshirbiny MF, Hafez RFA, Ali N, Ezzeldien AS, Kassem MA (2015) Role of gamma knife radiosurgery in the management of functioning pituitary adenomas. Benha Med J 32:6–12CrossRef Elshirbiny MF, Hafez RFA, Ali N, Ezzeldien AS, Kassem MA (2015) Role of gamma knife radiosurgery in the management of functioning pituitary adenomas. Benha Med J 32:6–12CrossRef
36.
Zurück zum Zitat Cohen-Inbar O, Xu Z, Schlesinger D, Vance MR, Sheehan JP (2015) Gamma Knife radiosurgery for medically and surgically refractory prolactinomas: long-term results. Pituitary 18:820–830CrossRefPubMed Cohen-Inbar O, Xu Z, Schlesinger D, Vance MR, Sheehan JP (2015) Gamma Knife radiosurgery for medically and surgically refractory prolactinomas: long-term results. Pituitary 18:820–830CrossRefPubMed
37.
Zurück zum Zitat Ježková J, Marek J, Hána V et al (2006) Gamma knife radiosurgery for acromegaly—long-term experience. Clin Endocrinol 64:588–595CrossRef Ježková J, Marek J, Hána V et al (2006) Gamma knife radiosurgery for acromegaly—long-term experience. Clin Endocrinol 64:588–595CrossRef
38.
Zurück zum Zitat Marek J, Ježková J, Hána V et al (2015) Gamma knife radiosurgery for Cushing´s disease and Nelson´s syndrome. Pituitary 18(3):376–384CrossRefPubMed Marek J, Ježková J, Hána V et al (2015) Gamma knife radiosurgery for Cushing´s disease and Nelson´s syndrome. Pituitary 18(3):376–384CrossRefPubMed
39.
Zurück zum Zitat Webster J, Piscitelli G, Polli A, Alberton A, Falsetti L, Ferrari C, Fioretti P, Giordano G, Hermite M, Ciccarelli E, European Multicenter.: Cabergoline Dose-finding Study Group (1992) Dose depend suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicenter Cabergoline Dose-findng Study Group. Clin Endocrinol 37:534–541CrossRef Webster J, Piscitelli G, Polli A, Alberton A, Falsetti L, Ferrari C, Fioretti P, Giordano G, Hermite M, Ciccarelli E, European Multicenter.: Cabergoline Dose-finding Study Group (1992) Dose depend suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicenter Cabergoline Dose-findng Study Group. Clin Endocrinol 37:534–541CrossRef
40.
Zurück zum Zitat Shimon I, Benbassat C, Hadani M (2007) Effectivness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 156:225–231CrossRefPubMed Shimon I, Benbassat C, Hadani M (2007) Effectivness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol 156:225–231CrossRefPubMed
41.
Zurück zum Zitat Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29–38CrossRefPubMed Schade R, Andersohn F, Suissa S, Haverkamp W, Garbe E (2007) Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med 356:29–38CrossRefPubMed
42.
Zurück zum Zitat Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson´s disease. N Engl J Med 356(1):39–46CrossRefPubMed Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G (2007) Valvular heart disease and the use of dopamine agonists for Parkinson´s disease. N Engl J Med 356(1):39–46CrossRefPubMed
43.
Zurück zum Zitat Dekkers OM, Lagro J, Burman P, Jorgensen JO, Romijn JA, Pereira AM (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95(1):43–51CrossRefPubMed Dekkers OM, Lagro J, Burman P, Jorgensen JO, Romijn JA, Pereira AM (2010) Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J Clin Endocrinol Metab 95(1):43–51CrossRefPubMed
44.
Zurück zum Zitat Iglesias P, Díez JJ (2013) Macroprolactinoma: a diagnostic and therapeutic update. QJM 106:495–504CrossRefPubMed Iglesias P, Díez JJ (2013) Macroprolactinoma: a diagnostic and therapeutic update. QJM 106:495–504CrossRefPubMed
45.
Zurück zum Zitat O’Connor MM, Mayberg MR (2000) Effects of radiation on cerebral vasculature: a review. Neurosurgery 46:138–149 (discussion 150-1) CrossRefPubMed O’Connor MM, Mayberg MR (2000) Effects of radiation on cerebral vasculature: a review. Neurosurgery 46:138–149 (discussion 150-1) CrossRefPubMed
46.
Zurück zum Zitat Akai T, Torigoe K, Fukushima M, Iizuka H, Hayashi Y (2015) De novo aneurysm formation following gamma knife surgery for arteriovenous malformation: a case report. J Neurol Surg Rep 76:e105–e108CrossRefPubMedPubMedCentral Akai T, Torigoe K, Fukushima M, Iizuka H, Hayashi Y (2015) De novo aneurysm formation following gamma knife surgery for arteriovenous malformation: a case report. J Neurol Surg Rep 76:e105–e108CrossRefPubMedPubMedCentral
48.
Zurück zum Zitat Ikeda H, Jokura H, Yoshimoto T et al (2001) Transsphenoidal surgery and adjuvant gamma knife treatment for growth hormone-secreting pituitary adenoma. J Neurosurg 95:285–291CrossRefPubMed Ikeda H, Jokura H, Yoshimoto T et al (2001) Transsphenoidal surgery and adjuvant gamma knife treatment for growth hormone-secreting pituitary adenoma. J Neurosurg 95:285–291CrossRefPubMed
49.
Zurück zum Zitat Feigl GC, Bonelli CM, Berghold A, Mokry M (2002) Effects of gamma knife radiosurgery of pituitary adenomas on pituitary function. J Neurosurg 97(Suppl 5):415–421CrossRefPubMed Feigl GC, Bonelli CM, Berghold A, Mokry M (2002) Effects of gamma knife radiosurgery of pituitary adenomas on pituitary function. J Neurosurg 97(Suppl 5):415–421CrossRefPubMed
50.
Zurück zum Zitat Leenstra JL, Tanaka S, Kline RW, Brown PD, Lnk MJ, Nippoldt TB, Young WF Jr, Pollock BE (2010) Factors associated with endocrine deficits after stereotactic radiosurgery of pituitary adenomas. Neurosurgery 67:27–33CrossRefPubMed Leenstra JL, Tanaka S, Kline RW, Brown PD, Lnk MJ, Nippoldt TB, Young WF Jr, Pollock BE (2010) Factors associated with endocrine deficits after stereotactic radiosurgery of pituitary adenomas. Neurosurgery 67:27–33CrossRefPubMed
Metadaten
Titel
Role of gamma knife radiosurgery in the treatment of prolactinomas
verfasst von
Jana Ježková
Václav Hána
Mikuláš Kosák
Michal Kršek
Roman Liščák
Josef Vymazal
Ladislav Pecen
Josef Marek
Publikationsdatum
20.06.2019
Verlag
Springer US
Erschienen in
Pituitary / Ausgabe 4/2019
Print ISSN: 1386-341X
Elektronische ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-019-00971-x

Weitere Artikel der Ausgabe 4/2019

Pituitary 4/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.